Posts Tagged: $3 billion
Robert Klein, left, and CIRM board member Jeff Sheey, right. At center is Board Vice Chair Art Torres. (Photo: California Stem Cell Report)
The two men once worked together over the last 16 years to spend $3 billion in state funds on stem cell research in California. This week, however, they were very publicly on opposite sides of a ballot initiative to spend $5.5 billion more. The initiative is Proposition 14, which would require the state to borrow the additional billions.
A cancer stem cell researcher in the laboratory. (Photo: science photo, via Shutterstock)
A $5.5 billion stem cell bond measure qualified this afternoon for the November ballot, but the campaign to win voter approval is facing an array of hurdles that its supporters never envisioned last summer when they were formulating the initiative.
A signature gatherer in Ventura during the 2018 election cycle. (Photo: Michael Gordon, via Shutterrstock)
Backers of a $5.5 billion stem cell research initiative in California have suspended their efforts to gather signatures to place it on the November ballot, but are expressing confidence that the proposal will qualify. The campaign said it had run afoul of statewide bans on public gatherings.
Signature gathering in Ventura County during the 2018 election cycle. (Photo: Michael Gordon, via Shutterstock)
The current coronavirus emergency and the practice of social distancing are likely to put a crimp in gathering signatures to qualify a $5.5 billion stem cell initiative for the November ballot in California.
A laboratory stem cell researcher uses a laptop in conjunction with a microscope. (Photo: moreimages, via Shutterstock)
A small firm in Menlo Park, Ca., is probably the only company in the nation that is named after the number of a particular human protein. It is a small number too, only 47. But it has large implications for California’s financially strapped state stem cell agency.
A liquid nitrogen bank containing stem cells.(Photo: Alena Pavlovich, via Shutterstock)
The $3 billion California stem cell agency on Monday served up the bad news with only a smattering of sugar coating. No more applications for research funding are being accepted. The cash is running out, perhaps as early as the end of August.
A stem cell researcher examines a vial in the laboratory. (Image: CI Photos, via Shutterstock)
In just nine days, the California stem cell agency will take a close look at its future, examining its budget for the coming fiscal year as well as the possibilities for a ballot initiative in 2020 that could stave off its financial demise. The $3 billion enterprise, known formally as the California Institute for Regenerative Medicine (CIRM), expects to run out cash for new research awards this year, perhaps as early as September.
A liquid nitrogen bank containing a suspension of stem cells. (Photo: Elena Pavlovich, via Shutterstock)
California’s stem cell agency gave away $14 million this month, which could be described as less than a drop in its $3 billion bucket. But the talk at the agency’s awards meeting July 19 was not about largess. Instead it was about the lack of cash, lack of time and the need to split “babies” and “buckets.”
An illustration of stem cells used in research. (Photo: Billion Photos, via Shutterstock)
California’s $3 billion stem cell research agency, which is facing its financial demise in a few short years, has formed a team of its directors to tackle transition planning and examine possible alternatives, including ones that would extend its life. The first meeting of the group of directors is tentatively scheduled for Sept. 18.
The Lorry I. Lokey stem cell research building at Stanford University, a major facility of the California Institute for Regenerative Medicine. (Photo: CIRM)
California’s $3 billion stem cell research program is looking for a new president to carry the state agency through what may be the last three years of its life. The search committee of the agency’s 29-member governing board meets July 17 to discuss the matter behind closed doors.